Advanced Search

 

Study ID Status Title Patient Level Data
VALF3002 Completed Multicentre, randomised, open-label study to compare the efficacy and safety of valaciclovir oral route and aciclovir intravenous route, to treat zoster in immunodeficient patients.
VAL-R19 Completed A Single-Center, Open-Label Study of the Safety and Pharmacokinetics of Valacyclovir in Children with Epstein-Barr Virus Illness Extensive searching has revealed that no clinical study report is available for this study. The clinical trial results were reported via publication; see citation below.
VAL-R56 Completed Acyclovir Concentrations in Human Breast Milk After Valaciclovir Administration. Extensive searching has revealed that no clinical study report is available for this study.
VALR94 Completed An Open-Label Pilot Study of valacyclovir (VALTREX) 2000 mg BID for One Day in the Episodic Treatment of Recurrent Genital Herpes
VEG10003 Completed A Phase I, Open-Label, Multiple Dose, Dose Escalation Study of GW786034 in Patients with Solid Tumors
VEG10004 Completed An Open-Label, Two-Part Study to Characterize the Pharmacokinetics of a Single Intravenous Dose of Pazopanib (GW786034) and the Absorption, Distribution, Metabolism and Elimination of a Single Oral [14C] Labeled Dose of Pazopanib in Subjects with Solid Tumor Malignancies
VEG10005 Completed An Open-Label, Two-Period, Randomized, Crossover Study to Evaluate the Effect of Food on the Pharmacokinetics of Single Doses of Pazopanib in Cancer Patients
VEG10006 Completed An Open-Label, Safety, Pharmacokinetic and Pharmacodynamic Study of Multiple Doses of GW786034 and Lapatinib Concomitantly Administered in Cancer Patients.
VEG10007 Completed A Multi-center, Open-Label, Multiple-probe Drug Interaction Study to Determine the Effects of GW786034 on the Metabolism of Cytochrome P450 Probe Drugs in Patients with Solid Tumors
VEG102616 Completed A Phase II Study of GW786034 Using a Randomised Discontinuation Design in Subjects with Locally Recurrent or Metastatic Clear-Cell Renal Cell Carcinoma
VEG102857 Completed Phase I and II, Open-Label, Multi-Center Trials of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma
VEG105192 Completed A Randomised, Double-blind, Placebo controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) Compared to Placebo in Patients with Locally Advanced and/or Metastatic Renal Cell Carcinoma
VEG105281 Completed A Phase II, Open-Label, Randomized, Multicenter Trial of Pazopanib (GW786034) in Combination with Lapatinib (GW572016) Compared to Pazopanib Monotherapy and Lapatinib Monotherapy in Subjects with FIGO Stage IVB or Recurrent or Persistent Cervical Cancer with Zero or One Prior Chemotherapy Regimen
VEG105290 Completed A Phase II Open-Label Multicenter Study to Evaluate the Safety and Efficacy of Pazopanib (GW786034) as Neoadjuvant Therapy in Treatment-Naïve Subjects with Stage IA, IB, IIA or IIB (to T2) Resectable Non-Small Cell Lung Cancer (NSCLC)
VEG105424 Completed An Open-Label, Pharmacokinetic Study of the Safety and Tolerability of Pazopanib in Combination with FOLFOX 6 or CapeOx in Subjects with Colorectal Cancer
VEG105427 Completed A Phase I, Open-Label, Study of the Safety, Tolerability and Pharmacokinetics of Pazopanib in Combination with Paclitaxel on a Weekly Schedule for 3 Consecutive Wks, Paclitaxel & Carboplatin on an Every 21 Days Schedule and Lapatinib & Paclitaxel on a Weekly Schedule for 3 Consecutive Weeks
VEG105430 Active not recruiting An Open-Label, Phase Ib Study to Assess the Long Term Safety Profile of Pazopanib in Cancer Patients
VEG107200 Completed A Phase I, Open-Label, Dose-Escalation, Multi-Center Study or Pazopanib (GW786034) in Adult Patients with Hepatocellular Cancer
VEG107769 Active not recruiting An open-label extension study to assess the safety and efficacy of pazopanib in subjects with renal cell carcinoma previously enrolled on protocol VEG105192
VEG108838 Completed A Randomized, Multicenter, Phase III Study Comparing the Combination of Pazopanib and Lapatinib versus Lapatinib Monotherapy in Patients with ErbB2 over-expressing Inflammatory Breast Cancer
VEG108925 Completed A phase I, Open label, Study of the safety, tolerability and pharmacokinetics of pazopanib in combination with irinotecan and cetuximab for the relapsed or refractory metastatic colorectal cancer
VEG109599 Completed A Phase I, Open-label, Study of the Safety, Tolerability and Pharmacokinetics of Pazopanib in Combination with Gemcitabine and Gemcitabine plus Cisplatin for Advanced Solid Tumors.
VEG109603 Completed A Phase I, Open-label, Study of the Safety, Pharmacokinetics, and Pharmacodynamics dose escalation of Pazopanib in Combination with Epirubicin or Doxorubicin for Advanced Solid Tumors
VEG109607 Completed A Phase I Study of Pazopanib in Combination with Either Erlotinib or Pemetrexed in Patients with Advanced Solid Tumors
VEG110190 Completed A Phase I/II, Open-Label, Multicenter, Two-Arm, Feasibility Study of Pazopanib, Carboplatin, and Paclitaxel in Women with Newly Diagnosed, Previously Untreated, Gynaecological Tumors

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.